CAMBRIDGE, Mass., April 08, 2020 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced.

Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. to develop a novel HSV-2 vaccine using Genocea’s proprietary HSV-2 antigens from the GEN-003 program, which the company discontinued in 2017. Under the terms of the agreement, Shionogi will pay $2 million for the exclusive option to evaluate the HSV-2 antigens and to negotiate a license prior to expiration of the MTA. Upon exercise of Shionogi’s option, terms of the license are expected to include an upfront payment, regulatory and sales milestones, as well as tiered royalties.

Q1 2020 Genocea Biosciences Inc Earnings Call

Q4 2019 Genocea Biosciences Inc Earnings Call

As of late, it has definitely been a great time to be an investor in Genocea Biosciences, Inc. (GNCA).

Additionally, Genocea will host a virtual KOL symposium with a live Q&A providing a brief review of the current T cell therapy landscape – including the evolution of TIL and TCR therapy utility, and the need for new approaches to better patient outcomes – on Tuesday, May 12th at 12 p.m. EDT. Members of the Genocea management team will also provide an overview of the development of GEN-011, a potential best-in-class solid tumor adoptive T cell therapy. Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types.

Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy – on Tuesday, May 12th at 12:00 p.m. EDT. Genocea will highlight GEN-011 as a potential best-in-class adoptive T cell therapy designed to improve upon the current limitations of TIL therapy. The event will also feature Eric Tran, Ph.D., Assistant Member at the Earle A. Chiles Research Institute in the Providence Cancer Institute, who will review the evolution of TIL and TCR solid tumor treatment approaches as part of ongoing efforts to improve patient outcomes for hard-to-address cancers.

CAMBRIDGE, Mass., Nov. 14, 2019 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced.

CAMBRIDGE, Mass., Feb. 26, 2020 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced.

Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, hosted a KOL symposium today with Dr. Eric Tran, Assistant Member at the Earle A. Chiles Research Institute in the Providence Cancer Institute reflecting on the T cell therapy landscape, while Genocea provided an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy. Genocea introduced data showing that GEN-011 embraces the advantages of TIL therapy while improving on its limitations.

Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present updated durability, safety and immunogenicity clinical data from Part A of its ongoing Phase 1/2a trial for GEN-009, the company’s lead neoantigen vaccine candidate at the virtual 2020 American Society for Clinical Oncology (ASCO) Annual Meeting from May 29-31. The analysis evaluates eight patients from Part A of the trial who were vaccinated with GEN-009 as adjuvant therapy, focusing on the onset and duration of induced immunity and clinical outcomes.

Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy – on Tuesday, May 12th at 12:00 p.m. EDT. Genocea management will highlight the potential for GEN-011 to become a best-in-class adoptive T cell therapy. The event will also feature Eric Tran, Ph.D., Assistant Member at the Earle A. Chiles Research Institute in the Providence Cancer Institute, who was previously involved in the seminal research at the National Cancer Institute (NCI) that initially demonstrated the promise of TIL therapy targeting cancer mutations.

The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

ATLASTM identifies Inhibigenstm that can undermine immunotherapyDosed first patient in Part B of GEN-009 neoantigen vaccine Phase 1/2a trialProgressed GEN-011 neoantigen cell.

CAMBRIDGE, Mass., Feb. 06, 2020 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its.

NEW YORK, April 21, 2020 -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Genocea Biosciences,.

CAMBRIDGE, Mass., Feb. 20, 2020 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced.

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Clinical stage programs GEN-009 and GEN-011 continue to advanceAnticipate GEN-011 IND filing in Q2Expect GEN-009 Phase 1/2a Part B readout in Q3GEN-011 Virtual Symposium planned.

Genocea Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.